Cul4B promotes the progression of ovarian cancer by upregulating the expression of CDK2 and CyclinD1

Peng-Jing Duan,Juan-Hong Zhao,Li-Li Xie

doi:10.1186/s13048-020-00677-w

Abstract

BackgroundOvarian cancer is one of the most common malignant tumors in the female reproductive system with the highest mortality rate. Cul4B participates in the oncogenesis and progression of several malignant tumors. However, the role of Cul4B in ovarian cancer has not been studied.ResultsHigh expression of intratumor Cul4B was associated with poor patient survival. Cul4B expression was associated with FIGO stage and Cul4B was independent risk factor of ovarian cancer disease-free survival and overall survival. In vitro studies revealed that overexpression of Cul4B promoted tumor proliferation while knockdown of Cul4B significantly inhibited the proliferation capacity of ovarian cancer cells. Mechanistically, Cul4B was found to promotes cell entering S phase from G0/G1 phase by regulating the expression of CDK2 and CyclinD1. Cul4B regulates the expression of CDK2 and CyclinD1 by repressing miR-372.ConclusionsThe results revealed that high expression of Cul4B is associated with poor ovarian cancer prognosis and Cul4B may serve as a potential treating target for an adjuvant therapy.

Highlights

Ovarian cancer is one of the most common malignant tumors in the female reproductive system [1]
The results revealed that intratumor Cul4B expression was associated with Federation of Gynecology and Obstetrics (FIGO) stage (Table 1)
Univariate and multivariate analysis revealed that tumor grade and intratumor Cul4B expression are independent risk factors of patient disease-free survival while tumor grade, FIGO stage and intratumor Cul4B expression are identified as independent risk factors of patient overall survival (Table 2)

Summary

Introduction

Ovarian cancer is one of the most common malignant tumors in the female reproductive system [1]. The incidence rate of ovarian cancer ranks third while the mortality rate ranks first among all kinds of gynecological malignant tumors [2]. The 5-year survival rates of ovarian cancer in stages III and IV are less than 40 and 20%, respectively, which is a serious threat to women’s health [3]. The early stage symptoms of ovarian cancer are insidious, and metastasis often occurs before the symptoms. Ovarian cancer is one of the most common malignant tumors in the female reproductive system with the highest mortality rate. The role of Cul4B in ovarian cancer has not been studied

Objectives

Methods

Results

Discussion

Conclusion